DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August10, 2017, Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June30, 2017. A copy of the press release is furnished herewith as Exhibit99.1.
On August3, 2017, the Company announced that it would hold a conference call and live audio webcast at 4:30 p.m., Eastern Time, on August10, 2017, to discuss its financial and operational results and to provide a general business update.
The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
| Item 2.02 | Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
| 99.1 | Press Release, entitled “Dicerna Reports Second Quarter 2017 Financial and Operational Results and Provides Corporate Update.” |
Dicerna Pharmaceuticals Inc ExhibitEX-99.1 2 d436129dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Dicerna Reports Second Quarter 2017 Financial and Operating Results and Provides Corporate Update Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE,…To view the full exhibit click here
About DICERNA PHARMACEUTICALS, INC. (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).
